Follow
MARÍA DÍEZ CAMPELO
MARÍA DÍEZ CAMPELO
Médico Adjunto, Servicio de Hematología, Hospital Universitario de Salamanca
Verified email at usal.es
Title
Cited by
Cited by
Year
The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes
S Tabera, JA Pérez-Simón, M Díez-Campelo, LI Sánchez-Abarca, ...
haematologica 93 (9), 1301-1309, 2008
3232008
Luspatercept in patients with lower-risk myelodysplastic syndromes
P Fenaux, U Platzbecker, GJ Mufti, G Garcia-Manero, R Buckstein, ...
New England Journal of Medicine 382 (2), 140-151, 2020
2482020
Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification
S Carrancio, N López-Holgado, FM Sánchez-Guijo, E Villarón, V Barbado, ...
Experimental hematology 36 (8), 1014-1021, 2008
2032008
Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial
JA Pérez-Simon, O López-Villar, EJ Andreu, J Rifón, S Muntion, ...
haematologica 96 (7), 1072, 2011
1782011
Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q− syndrome
O Lopez-Villar, JL Garcia, FM Sanchez-Guijo, C Robledo, EM Villarón, ...
Leukemia 23 (4), 664-672, 2009
1612009
Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft‐versus‐host disease after allogeneic transplantation
JA Pérez‐Simón, M Díez‐Campelo, R Martino, S Brunet, Á Urbano, ...
British journal of haematology 130 (3), 394-403, 2005
1372005
Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation
JA Perez-Simon, D Caballero, M Diez-Campelo, R Lopez-Perez, ...
Leukemia 16 (8), 1423-1431, 2002
1302002
Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation
JA Pérez-Simón, M Díez-Campelo, R Martino, A Sureda, D Caballero, ...
Blood 102 (3), 1108-1113, 2003
1242003
Comparison of ex vivo expansion culture conditions of mesenchymal stem cells for human cell therapy
M Pérez‐Ilzarbe, M Díez‐Campelo, P Aranda, S Tabera, T Lopez, ...
Transfusion 49 (9), 1901-1910, 2009
1192009
Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease
F Sánchez-Guijo, T Caballero-Velázquez, O López-Villar, A Redondo, ...
Biology of Blood and Marrow Transplantation 20 (10), 1580-1585, 2014
1072014
Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena
EM Ocio, FM Sanchez‐Guijo, M Diez‐Campelo, C Castilla, OJ Blanco, ...
American journal of hematology 78 (4), 302-305, 2005
1062005
Response to lenalidomide in myelodysplastic syndromes with del (5q): influence of cytogenetics and mutations
M Mallo, M Del Rey, M Ibanez, MJ Calasanz, L Arenillas, MJ Larráyoz, ...
British journal of haematology 162 (1), 74-86, 2013
1012013
Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients
C Santamaría, S Muntión, B Rosón, B Blanco, O López-Villar, S Carrancio, ...
haematologica 97 (8), 1218, 2012
962012
Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of …
JA Pérez-Simón, C Encinas, F Silva, MJ Arcos, M Díez-Campelo, ...
Biology of Blood and Marrow Transplantation 14 (10), 1163-1171, 2008
952008
Chronic graft-versus-host disease
JA Perez-Simon, I Sanchez-Abarca, M Diez-Campelo, D Caballero, ...
Drugs 66 (8), 1041-1057, 2006
932006
Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population
B Blanco, JA Pérez-Simón, LI Sánchez-Abarca, T Caballero-Velazquez, ...
haematologica 94 (7), 975, 2009
722009
Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents
S Park, JF Hamel, A Toma, C Kelaidi, S Thépot, MD Campelo, V Santini, ...
Journal of Clinical Oncology 35 (14), 1591-1597, 2017
712017
Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications
ÁF Remacha, B Arrizabalaga, A Villegas, MS Durán, L Hermosín, ...
Annals of hematology 94 (5), 779-787, 2015
672015
Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura
JA Pérez-Simón, S Tabera, ME Sarasquete, M Díez-Campelo, ...
Cytotherapy 11 (6), 698-705, 2009
672009
The Medalist trial: results of a phase 3, randomized, double-blind, placebo-controlled study of luspatercept to treat anemia in patients with very low-, low-, or intermediate …
P Fenaux, U Platzbecker, GJ Mufti, G Garcia-Manero, R Buckstein, ...
Blood 132, 1, 2018
652018
The system can't perform the operation now. Try again later.
Articles 1–20